Status:
COMPLETED
Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
Lead Sponsor:
Pfizer
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This study is to evaluate the local data in Iraqi patients with psoriatic arthritis on Enbrel treatment with positive Anti-Cyclic Citrullinated Peptide using data from the Rheumatologist in Baghdad Te...
Eligibility Criteria
Inclusion
- Diagnosed PsA patients.
- ≥18 years of age
- Have not received previous biological treatment
Exclusion
- Previous use of other biological treatments.
- Etanercept use for less than 1 year duration.
Key Trial Info
Start Date :
July 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2020
Estimated Enrollment :
127 Patients enrolled
Trial Details
Trial ID
NCT04428502
Start Date
July 5 2020
End Date
August 30 2020
Last Update
September 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Baghdad, Iraq